O'Banion v. Owens-Corning Fiberglas Corp.

968 F.2d 1011, 1992 U.S. App. LEXIS 14896, 1992 WL 146751
CourtCourt of Appeals for the Tenth Circuit
DecidedJune 30, 1992
DocketNo. 90-5175
StatusPublished
Cited by1 cases

This text of 968 F.2d 1011 (O'Banion v. Owens-Corning Fiberglas Corp.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Tenth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
O'Banion v. Owens-Corning Fiberglas Corp., 968 F.2d 1011, 1992 U.S. App. LEXIS 14896, 1992 WL 146751 (10th Cir. 1992).

Opinion

SAFFELS, District Judge.

This is a products liability and negligence action brought under Oklahoma law. Plaintiff-appellants alleged that Stanley O’Banion suffered from asbestos-related disease as a result of exposure to the defendant-appellees’ asbestos-containing products.1 Plaintiff Stanley John O’Banion worked from 1962 through 1980 as a plumber and pipefitter. Following a one week trial, beginning on June 21, and ending on June 29, 1990, a verdict for the defendants was rendered.

On appeal, plaintiff-appellants contend that the district court erred in its pre-trial rulings which resulted in the exclusion of evidence relating to cancer and in striking plaintiffs’ civil conspiracy claim. Appellants also contend that the trial court erred in admitting into evidence trial testimony given by an expert witness at a previous trial in a different case. Appellants also contend that the trial court erred in instructing the jury on “state of the art” as it relates to plaintiffs’ products liability claim.

I. Exclusion of evidence relating to Cancer

Appellants first contend on appeal that the district court erred in excluding evidence relating to “cancer” during the trial. Appellants argue that this evidence is relevant to the following issues: (1) whether the manufacturers have fulfilled their duty to test for toxic effects of their products; (2) whether they have satisfactorily informed and warned foreseeable users of all the hazards associated with asbestos use; and (3) whether the hazards of asbestos, taken together are so great that they outweigh the utility of the substance so that asbestos is an ultra hazardous product which should not have been marketed at all.

Prior to commencing the trial below, which was one of approximately 600 asbestos-related cases arising out of the Northern District of Oklahoma, Chief Judge Dale Cook, Judge Brett, and Judge Ellison (the presiding judge in the instant case) issued a Master Order in which numerous pretrial motions were addressed and ruled upon. One of these motions was the defendant-appellees’ motion to preclude the mention of the word “cancer” or the presentation of any evidence relating to cancer in “non-cancer” asbestos cases. See Master Order, filed July 28, 1989 (Case No. 87-C-522-B) (Appellants’ Brief in Chief, Attachment 4, at 6). In the Master Order, the court granted defendant Owens-Fiberglas Corporation’s motion in limine to exclude evidence relevant to plaintiffs’ claim for dam[1013]*1013ages due to increased risk of cancer or fear of cancer in cases where no diagnosis of carcinogenic asbestos-related disease or evidence of a reasonable medical probability of same exists. (Appellants’ Brief in Chief, Attachment 4, at 21-22). In reaching this conclusion, the court found as follows:

“(1) No Oklahoma authority supports admissibility of such evidence;
(2) It is too speculative; and
(3) Because of (2) above, even if relevant, such should not be admitted in evidence because of danger of unfair prejudice or confusion of the issues to the jury as provided in Federal Rule of Evidence 403.”

Id. 2

Plaintiffs later moved to permit the mention of cancer in reports of qualified experts regarding whether defendants had notice of the increased risk of cancer thereby creating a duty to warn. (Appellants’ Brief in Chief, Attachment 2). The court denied plaintiffs’ request and further defined a “noncancer case” as “one in which no admissible evidence is offered on behalf of the Plaintiff from a qualified medical expert stating that there is a reasonable medical probability the Plaintiff will have a cancer condition from his asbestos related disease.” Id. n. 1.

Whether the trial court erred in precluding plaintiffs from mentioning cancer and from introducing evidence relating to cancer on grounds that its prejudicial value outweighs its probative value pursuant to Fed.R.Evid. 403 is reviewed under an abuse of discretion standard. See C.A. Assoc. v. Dow Chemical Co., 918 F.2d 1485, 1489 (10th Cir.1990). In this regard, “[t]he trial court is given broad discretion in the Rule 403 balancing analysis.” Durtsche v. American Colloid Co., 958 F.2d 1007, 1012 (10th Cir.1992).

We affirm the district court’s ruling on' this issue. A review of the record reflects that this case does not involve mesothelio-ma or other carcinogenic disease, nor did the plaintiff proffer expert testimony that there was a reasonable medical probability of his developing cancer from his alleged exposure to asbestos. Further, to date there is no Oklahoma case law which addresses whether damages may be recovered for the fear of an increased risk of developing cancer later in life. However, generally under Oklahoma law, damages which are purely speculative are- nonreeov-erable. See St. John’s Hosp. & School of Nursing, Inc. v. Chapman, 434 P.2d 160, 175 (Okla.1967); Maples v. Bryce, 429 P.2d 741, 743 (Okla.1967); Tom P. McDermott, Inc. v. Birks, 395 P.2d 575, 576 (Okla.1964). Thus, to the extent that plaintiffs did not make a proffer of expert medical testimony that there was a reasonable medical probability that plaintiff Stanley O’Banion would develop a cancerous condition from his exposure to asbestos, references to cancer were properly excluded due to lack of relevance.

To the extent that this evidence is arguably relevant to whether the defendant manufacturers had a duty to test and a duty to warn, see Jackson v. Johns-Manville Sales Corp., 781 F.2d 394, 409 (5th Cir.) (en banc), cert. denied, 478 U.S. 1022, 106 S.Ct. 3339, 92 L.Ed.2d 743 (1986), we agree with those courts which have held that evidence of cancer is so prejudicial that in the absence of expert medical testimony that a “reasonable degree of medical certainty” exists that the plaintiff will develop cancer, such evidence should be excluded. See Lohrmann v. Pittsburgh Corning Corp., 782 F.2d 1156, 1160 (4th Cir.1986) (under Maryland law, evidence is not admissible to prove damages where there is less than a reasonable probability that plaintiff will develop cancer) Adams v. Johns-Manville Sales Corp., 783 F.2d 589 (5th Cir.1986) (same); Jackson v. Johns-Manville Sales Corp., 750 F.2d 1314, 1319-21 (5th Cir.1985) (en banc) (plaintiff had greater than fifty-percent chance of con[1014]*1014tracting asbestos-related cancer in the future so cancer-related evidence was admissible); Gideon v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
968 F.2d 1011, 1992 U.S. App. LEXIS 14896, 1992 WL 146751, Counsel Stack Legal Research, https://law.counselstack.com/opinion/obanion-v-owens-corning-fiberglas-corp-ca10-1992.